HTG Molecular Announces Extension to Precision Diagnostic Partnership (PDP) Program Three for Companion Diagnostic Submission
TUCSON, Ariz., Sept. 27, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has entered into an amendment to the third statement of work (“SOW Three”) under its Master Assay Development, Commercialization and Manufacturing Agreement with QIAGEN Manchester Limited (“QIAGEN”).
- Category:
- Press Releases